3,4 dihydroxyphenyl ethanol reduces secretion of angiogenin in human retinal pigment epithelial cells

British Journal of Ophthalmology

Volumn 97, Issue 3, 2013, Pages 371-374

  Granner, Tamara ^a   Maloney, Shawn ^a   Antecka, Emilia ^a   Correa, José A ^a   Burnier, Miguel N ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIN; ANGIOPOIETIN 2; BEVACIZUMAB; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; HYDROXYTYROSOL; LEPTIN; PLATELET DERIVED GROWTH FACTOR BB; SCATTER FACTOR; VASCULOTROPIN A;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; PIGMENT EPITHELIUM; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTIOXIDANTS; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MACULAR DEGENERATION; PHENYLETHYL ALCOHOL; RETINAL PIGMENT EPITHELIUM; RIBONUCLEASE, PANCREATIC;

EID: 84874654717     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2012-302002     Document Type: Article

References (25)

1. Evans JR, Lawrenson JG. Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration. Cochrane Database Syst Rev 2012;(6): CD000253.
2. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122:564-72.
3. Newsome DA. A randomized, prospective, placebo-controlled clinical trial of a novel zinc-monocysteine compound in age-related macular degeneration. Curr Eye Res 2008;33:591-8.
4. Forooghian F, Kertes PJ, Eng KT, et al. Alterations in the intraocular cytokine milieu after intravitreal bevacizumab. Invest Ophthalmol Vis Sci 2010;51:2388-92.
5. Covas MI, Nyyssonen K, Poulsen HE, et al. The effect of polyphenols in olive oil on heart disease risk factors: a randomized trial. Ann Intern Med 2006;145:333-41.
6. Tuck KL, Hayball PJ. Major phenolic compounds in olive oil: metabolism and health effects. J Nutr Biochem 2002;13:636-44.
7. Owen RW, Haubner R, Wurtele G, et al. Olives and olive oil in cancer prevention. Eur J Cancer Prev 2004;13:319-26.
8. Manna C, Galletti P, Cucciolla V, et al. Olive oil hydroxytyrosol protects human erythrocytes against oxidative damages. J Nutr Biochem 1999;10:159-65.
9. Zhang X, Cao J, Zhong L. Hydroxytyrosol inhibits pro-inflammatory cytokines, iNOS, and COX-2 expression in human monocytic cells. Naunyn Schmiedebergs Arch Pharmacol 2009;379:581-6.
10. Zhu L, Liu Z, Feng Z, et al. Hydroxytyrosol protects against oxidative damage by simultaneous activation of mitochondrial biogenesis and phase II detoxifying enzyme systems in retinal pigment epithelial cells. J Nutr Biochem 2010;21:1089-98.
11. Cruess AF, Berger A, Colleaux K, et al. Canadian expert consensus: optimal treatment of neovascular age-related macular degeneration. Can J Ophthalmol 2012;47:227-35.
12. Wang B, Zou Y, Yuan ZL, et al. Genistein suppressed upregulation of vascular endothelial growth factor expression by cobalt chloride and hypoxia in rabbit retinal pigment epithelium cells. J Ocul Pharmacol Ther 2003;19:457-64.
13. Hara A, Niwa M, Aoki H, et al. A new model of retinal photoreceptor cell degeneration induced by a chemical hypoxia-mimicking agent, cobalt chloride. Brain Res 2006;1109:192-200.
14. Xiang N, Zhao MJ, Li XY, et al. Redundant mechanisms for vascular growth factors in retinopathy of prematurity in vitro. Ophthalmic Res 2011;45:92-101.
15. Luthra S, Narayanan R, Marques LE, et al. Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina 2006;26:512-18.
16. Spitzer MS, Wallenfels-Thilo B, Sierra A, et al. Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. Br J Ophthalmol 2006;90:1316-21.
17. Richer S, Stiles W, Statkute L, et al. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial). Optometry, 2004;75:216-30.
18. Terzuoli E, Donnini S, Giachetti A, et al. Inhibition of hypoxia inducible factor-1alpha by dihydroxyphenylethanol, a product from olive oil, blocks microsomal prostaglandin-E synthase-1/vascular endothelial growth factor expression and reduces tumor angiogenesis. Clin Cancer Res 2010;16:4207-16.
19. Ozaki H, Hayashi H, Oshima K. Angiogenin levels in the vitreous from patients with proliferative diabetic retinopathy. Ophthalmic Res 1996;28:356-60.
20. Marek N, Raczynska K, Siebert J, et al. Decreased angiogenin concentration in vitreous and serum in proliferative diabetic retinopathy. Microvasc Res 2011;82:1-5.
21. Kishimoto K, Liu S, Tsuji T, et al. Endogenous angiogenin in endothelial cells is a general requirement for cell proliferation and angiogenesis. Oncogene 2005;24:445-56.
22. Fett JW, Strydom DJ, Lobb RR, et al. Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells. Biochemistry 1985;24:5480-6.
23. Shapiro R, Fox EA, Riordan JF. Role of lysines in human angiogenin: chemical modification and site-directed mutagenesis. Biochemistry 1989;28:1726-32.
24. Bodner-Adler B, Hefler L, Bodner K, et al. Serum levels of angiogenin (ANG) in invasive cervical cancer and in cervical intraepithelial neoplasia (CIN). Anticancer Res 2001;21:809-12.
25. Skeie JM, Zeng S, Faidley EA, et al. Angiogenin in age-related macular degeneration. Mol Vis 2011;17:576-82.